Hot Natural Products & Bioactive Compounds

BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.

Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.

Hot Products from BioCrick

Showing 481 - 488 of 9359 hot products

BioCrick hot natural products and bioactive compounds
Catalog No. Product Name
BCC2427 TCS HDAC6 20b
Selective inhibitor of histone deacetylase 6 (HDAC6). Inhibits HCT116 growth in combination with taxol. Also inhibits growth of MCF-7 cells stimulated by estrogen.
BCC2429 Chaetocin
Histone methyltransferase SUV39H1 inhibitor (IC50 = 0.8 μM). Induces apoptosis in myeloma cell lines in vitro; exhibits antiproliferative activity in a mouse myeloma model in vivo.
BCC2430 UNC 0224
Potent G9a and GLP inhibitor (IC50 values are 15 and 20 nM in a ThioGlo assay, respectively). Exhibits >1000-fold selectivity for G9a over SET7, SET8 and SET9.
BCC2431 UNC 0646
Potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC<sub>50</sub> values are 6 nM and 15 nM for G9a and GLP, respectively). Potently blocks G9a/GLP methyltransferase activity in cells (IC<sub>50</sub> = 10 nM in MCF7 cells); exhibits low cellular toxicity (EC<sub>50</sub> = 4.7 <span class='symbol'>&#956;</span>M in MCF7 cells). Selective for G9a/GLP over a range of other protein lysine methyltransferases and protein arginine methyltransferases.
BCC2433 DMOG
Prolyl 4-hydroxylase (P4H) inhibitor; inhibits hypoxia-inducible factor <span class='symbol'>&#945;</span> (HIF-<span class='symbol'>&#945;</span>) prolyl hydroxylase (HIF-PH). Increases levels of HIF-1<span class='symbol'>&#945;</span>; promotes cell survival under hypoxic conditions.
BCC2434 KC7F2
Inhibitor of HIF-1<span class='symbol'>&#945;</span>. Thought to act via down-regulation of HIF-1<span class='symbol'>&#945;</span> protein synthesis; reduces phosphorylation of eIF4E binding protein 1 (4EBP1) and p70 S6K in hypoxic conditions. Also blocks hypoxia-induced HIF-1<span class='symbol'>&#945;</span> accumulation in a range of human cancer cell lines. Inhibits the expression of HIF target genes, such as carbonic anhydrase IX and MMP2.
BCC2435 ML 228
HIF pathway activator (EC<sub>50</sub> values are 1.23 and 1.4 <span class='symbol'>&#956;</span>M for HRE gene reporter assay and HIF-1<span class='symbol'>&#945;</span> nuclear translocation assay respectively); acts via chelation of iron, independently of PHD. Also exhibits &#062; 80% inhibition of the human A<sub>3</sub> receptor, dopamine transporter, <span class='symbol'>&#956;</span> receptor, hERG and 5-HT<sub>2B</sub> receptor, and rat sodium channel site 2, at a concentration of 10 <span class='symbol'>&#956;</span>M.
BCC2436 PX 12
Thioredoxin-1 (Trx-1) inhibitor; irreversibly inactivates Trx-1 as a substrate for reduction by thioredoxin reductase (TR); competitively inhibits the reduction of Trx-1 by TR (K<sub>i</sub> = 30.8 <span class='symbol'>&#956;</span>M). Attenuates expression of HIF-1<span class='symbol'>&#945;</span>, VEGF and iNOS (IC<sub>50</sub> values are 7.2, 10.4 and 18.1 <span class='symbol'>&#956;</span>M respectively). Exhibits antitumor activity; directly inhibits tubulin <em>in vitro</em> and decreases tumor microvessel density <em>in vivo</em>.